These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 27524864)
1. Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials. Marini S; De Berardis D; Vellante F; Santacroce R; Orsolini L; Valchera A; Girinelli G; Carano A; Fornaro M; Gambi F; Martinotti G; Di Giannantonio M Mediators Inflamm; 2016; 2016():3476240. PubMed ID: 27524864 [TBL] [Abstract][Full Text] [Related]
2. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Müller N; Riedel M; Scheppach C; Brandstätter B; Sokullu S; Krampe K; Ulmschneider M; Engel RR; Möller HJ; Schwarz MJ Am J Psychiatry; 2002 Jun; 159(6):1029-34. PubMed ID: 12042193 [TBL] [Abstract][Full Text] [Related]
3. Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trial. Strube W; Aksar A; Bauer I; Barbosa S; Benros M; Blankenstein C; Campana M; Davidovic L; Glaichenhaus N; Falkai P; Görlitz T; Hansbauer M; Heilig D; Khalfallah O; Leboyer M; Martinuzzi E; Mayer S; Moussiopoulou J; Papazova I; Perić N; Wagner E; Schneider-Axmann T; Simon J; Hasan A J Neural Transm (Vienna); 2023 Aug; 130(8):1039-1048. PubMed ID: 36401749 [TBL] [Abstract][Full Text] [Related]
4. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Basan A; Kissling W; Leucht S Schizophr Res; 2004 Sep; 70(1):33-7. PubMed ID: 15246461 [TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory strategies in the treatment of schizophrenia. Andrade C Expert Rev Clin Pharmacol; 2016; 9(2):161-3. PubMed ID: 26427750 [TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature. Jeste DV; Dolder CR; Nayak GV; Salzman C Harv Rev Psychiatry; 2005; 13(6):340-51. PubMed ID: 16373328 [TBL] [Abstract][Full Text] [Related]
12. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Müller N; Ulmschneider M; Scheppach C; Schwarz MJ; Ackenheil M; Möller HJ; Gruber R; Riedel M Eur Arch Psychiatry Clin Neurosci; 2004 Feb; 254(1):14-22. PubMed ID: 14991374 [TBL] [Abstract][Full Text] [Related]
13. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Stip E; Tourjman V Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550 [TBL] [Abstract][Full Text] [Related]
14. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718 [TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects. Chen AT; Chibnall JT; Nasrallah HA Ann Clin Psychiatry; 2015 Nov; 27(4):289-96. PubMed ID: 26554370 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Chakos M; Lieberman J; Hoffman E; Bradford D; Sheitman B Am J Psychiatry; 2001 Apr; 158(4):518-26. PubMed ID: 11282684 [TBL] [Abstract][Full Text] [Related]
17. COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. Riedel M; Strassnig M; Schwarz MJ; Müller N CNS Drugs; 2005; 19(10):805-19. PubMed ID: 16185091 [TBL] [Abstract][Full Text] [Related]
18. Emerging Treatments in Schizophrenia: Highlights from Recent Supplementation and Prevention Trials. Brown HE; Roffman JL Harv Rev Psychiatry; 2016; 24(2):e1-7. PubMed ID: 26954600 [TBL] [Abstract][Full Text] [Related]
19. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
20. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Edwards SJ; Smith CJ Clin Ther; 2009 Jun; 31 Pt 1():1345-59. PubMed ID: 19698898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]